Q1 EPS Estimates for Ascendis Pharma A/S Lowered by Wedbush

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at Wedbush reduced their Q1 2025 earnings per share estimates for Ascendis Pharma A/S in a research report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will post earnings per share of ($1.76) for the quarter, down from their previous estimate of ($1.58). Wedbush has a “Outperform” rating and a $181.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s Q2 2025 earnings at ($1.24) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($4.84) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at $2.96 EPS and FY2028 earnings at $9.17 EPS.

Several other research analysts have also issued reports on the company. The Goldman Sachs Group boosted their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. UBS Group assumed coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 11th. Finally, Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $193.43.

Ascendis Pharma A/S Trading Up 1.1 %

Shares of ASND opened at $144.08 on Monday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The company’s fifty day simple moving average is $132.41 and its 200-day simple moving average is $132.34. The company has a market cap of $8.74 billion, a P/E ratio of -17.83 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth $30,000. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. grew its stake in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares during the last quarter. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares in the last quarter. Finally, Signaturefd LLC raised its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.